However, given the large differences between CPs’ direct binding affinities to BCL-2/BCL-XL proteins (Table 1) and their cellular activities (Figs. 5 and 6), we could not fully rule out the possibility that certain off-target effects are also involved in the inhibition by CPs on these tumor cells. Here, BCL2 is linked to neoplasm.